Can Diet Calm Inflammatory Skin Disease?

If you’ve experienced a bad case of poison ivy, or maybe been the target of a mischievous itching-powder prank, then you know how consuming the itching and scratching can be. Luckily, these are temporary ailments, usually resolved fairly quickly. For those living with chronic dermatitis, however, the constant irritation can be debilitating.

Ulcerative dermatitis is a condition seen specifically in laboratory mice, but it is often used as a model for human disease, especially atopic dermatitis, because the two share several underlying causes and similar features. In mice, this condition reflects a breakdown in inflammatory control that leads to painful, itchy skin ulcers. Diseases rooted in inflammation are often complex because inflammation itself is a double-edged sword. It is essential for the body’s ability to protect and repair tissue following injury, yet it can become destructive when excessive or poorly regulated. Like Goldilocks’ porridge, i

nflammation must be “just right”—too little and it leaves itself vulnerable, too much and the body turns on itself.

The complicated nature of ulcerative dermatitis makes it difficult to treat. The scope and severity of inflammatory dysregulation are influenced by numerous underlying factors—including age, nutrition, metabolic health, psychological stress, and a variety of others. These same factors, however, may also offer opportunities to dial down inflammation. A recent study published in the Journal of Inflammation explored two dietary strategies aimed at alleviating this treatment-resistant condition through metabolic pathways. The work builds upon prior research from the group’s investigation of methionine restriction.

Methionine restriction is a well-studied dietary intervention shown to extend lifespan in laboratory animals and to improve multiple aspects of metabolic health. However, sustained restriction is difficult to implement in humans due to the abundance of methionine in typical diets. To address this limitation, the investigators evaluated two alternative approaches: intermittent methionine restriction, limited to three days per week, and sodium selenite supplementation, which has been shown to recapitulate several metabolic effects of methionine restriction.

Given the well-established link between metabolic dysfunction and chronic inflammation, the researchers asked whether either intervention could delay the development of inflammation-associated ulcerative dermatitis.

What They Found

C57BL/6 (B6) mice—one of the most widely used laboratory strains—are particularly prone to age- associated ulcerative dermatitis. To speed things up, the animals were fed a high-fat diet, which promotes obesity and metabolic dysregulation. Separate groups received either intermittent methionine restriction or sodium selenite supplementation.

Both interventions significantly delayed the onset of dermatitis, although to differing degrees. Intermittent methionine restriction delayed the median time to lesion appearance by 44%, while selenium supplementation produced an 89% delay, demonstrating a robust protective effect.

Mechanistically, the high-fat diet induced obesity and elevated circulating leptin levels. Leptin, a hormone secreted by adipose tissue (fat), is known to promote inflammatory signaling and enhance production of IL-17, a signaling molecule implicated in inflammatory skin pathology. Compared to control animals, mice receiving either intervention exhibited reduced leptin and IL-17 levels, consistent with suppression of a pro-inflammatory state. In addition, both treatment groups showed decreased levels of acute phase proteins—markers of inflammation—consistent with a shift in the systemic inflammatory state.

Collectively, these findings support the idea that metabolic status and adipose-derived signaling contribute to ulcerative dermatitis susceptibility. By modulating systemic inflammation—potentially through reductions in leptin-driven immune activation—these dietary interventions delayed disease onset in a high-risk model.

How This Helps

It is important to keep in mind that while this study is limited in scope and these results remain preclinical, they highlight an emerging principle: metabolic interventions may influence inflammatory skin conditions by acting upstream of inflammatory response.

Today, treatment options for atopic dermatitis range from dietary changes and topical therapies to phototherapy and, in more severe cases, systemic immunosuppressive drugs. Although these medications can be effective, they can also carry significant side effects. Interventions like this, which may help safely bring the inflammatory response back into balance, could eventually complement current therapies and potentially lessen the need for more aggressive drug treatments.